Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
Rhea-AI Summary
Cadrenal Therapeutics (Nasdaq: CVKD) reported a positive outcome from a July 28, 2026 FDA Type D meeting on the Phase 3 registration study of CAD-1005, a first-in-class 12-lipoxygenase inhibitor in development for heparin-induced thrombocytopenia (HIT). The FDA and Cadrenal aligned on key elements of the protocol and Statistical Analysis Plan, including an optimized composite primary endpoint based on adjudicated new or worsening thromboembolic events in Serotonin Release Assay-positive patients through Day 14 or hospital discharge.
According to Cadrenal Therapeutics, the FDA also agreed to a placebo-controlled design with standard anticoagulation in both arms and to assess bleeding as a major safety endpoint using International Society on Thrombosis and Haemostasis criteria, providing greater clarity on the regulatory path for CAD-1005’s Phase 3 program.
Positive
- FDA alignment on Phase 3 primary endpoint, protocol, and Statistical Analysis Plan for CAD-1005
- Agreement on placebo-controlled Phase 3 design with standard anticoagulation in both CAD-1005 and control arms
- Inclusion of ISTH-standard bleeding assessment as a major safety endpoint in the Phase 3 trial
Negative
- None.
Market reaction after Phase 3 regulatory alignment: CVKD +10.62%
Following this news, CVKD has gained 10.62%, reflecting a significant positive market reaction. Argus tracked a trough of -6.7% from its starting point during tracking. Our momentum scanner has triggered 9 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.70.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 03 | Multi-indication strategy | Positive | -2.5% | CAD-1005 strategy expanded across HIT and CSA-AKI indications |
| Jul 13 | Phase 2 clinical data | Positive | -16.3% | Phase 2 HIT data showed greater than 25% thrombotic-event reduction |
| Jun 24 | Phase 2 presentation | Neutral | -2.6% | CAD-1005 Phase 2 data selected for late-breaking oral presentation |
| Jun 03 | Partnering event | Neutral | -3.7% | Company planned partnering meetings for Phase 3-ready CAD-1005 |
| Apr 30 | Phase 3 registration path | Positive | +19.3% | FDA guidance supported advancing CAD-1005 into pivotal Phase 3 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical-trial announcements historically diverged from positive framing in four of five tag-matched events.
Key Terms
12-lipoxygenase (12-lox) medical
heparin-induced thrombocytopenia (hit) medical
statistical analysis plan (sap) technical
serotonin release assay-positive (sra+) medical
composite thromboembolic events (ctes) medical
international society on thrombosis and haemostasis (isth) criteria medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study
CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S. and an Estimated
PONTE VEDRA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced positive feedback from a Type D Meeting with the U.S. Food and Drug Administration (FDA) held on July 28, 2026. During the meeting, Cadrenal and the FDA aligned on key aspects of the protocol and Statistical Analysis Plan (SAP) for the Phase 3 registrational study of CAD-1005, the Company’s first-in-class 12-lipoxygenase (12-LOX) inhibitor in development to treat heparin-induced thrombocytopenia (HIT). HIT is a potentially life-threatening immune reaction to heparin, a widely used blood thinner, and can lead to dangerous blood clots.
In the U.S., heparin-induced thrombocytopenia (HIT) is a high-stakes emergency that affects approximately 50,000 patients with acute HIT each year. Current therapeutic options rely on standard anticoagulants to reduce thrombotic risk; however, they do not target the underlying immune mechanisms that drive this destructive cardiovascular cascade. CAD-1005 is a novel 12-LOX inhibitor designed to halt the core immune signaling pathway that drives platelet activation and vascular thrombosis. Developed as an essential add-on to standard anticoagulation, CAD-1005 targets a critical population and is projected to generate
During the Type D meeting, the FDA agreed on an optimized definition of worsening HIT for the primary endpoint, based on progression of thrombotic events through Day 14 of treatment or hospital discharge. To ensure high-quality, reliable endpoint evaluation across clinical sites, the worsening component of the primary endpoint will also include extension of an existing thrombus into a new vascular segment or bed, avoiding potential site-to-site variability from manual size measurements. The updated composite primary endpoint will measure the proportion of Serotonin Release Assay-positive (SRA+) participants with adjudicated new or worsening composite thromboembolic events (CTEs) through Day 14 or hospital discharge. Additionally, the FDA agreed to use placebo control in the Phase 3 trial, with standard anticoagulation therapeutics for both the CAD-1005 and placebo control arms.
"We are very pleased with the collaborative, constructive feedback from the FDA during this Type D meeting," said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. "Securing agreement on the primary endpoint definition and the blinding protocols for our saline control provides greater clarity on the regulatory path forward for CAD-1005. We have incorporated the Agency's recommendations into our Phase 3 protocol and Statistical Analysis Plan, strengthening the design of a registration study intended to evaluate whether CAD-1005 can reduce dangerous thrombotic events that persist in patients with HIT despite current anticoagulant therapies."
The Phase 3 trial design will also assess bleeding as a major safety endpoint using standard International Society on Thrombosis and Haemostasis (ISTH) criteria. All safety analyses will be conducted in the safety population of patients who receive at least one dose of the study drug.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions. The Company’s pipeline includes CAD-1005, tecarfarin, and frunexian. CAD-1005 is a novel investigational therapeutic in development for the treatment of heparin-induced thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). CAD-1005 is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling in HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that drive disease progression. CAD-1005 has an Orphan Drug Designation (“ODD”) from the U.S. Food and Drug Administration (“FDA”) for prophylaxis of thrombosis in patients with HIT, FDA Fast Track designation for the treatment and prevention of HIT, and an orphan designation from the European Medicines Agency for the treatment of platelet-activating factor 4 disorders. Second-generation 12-LOX oral therapeutics (CAD-2000) are also in development for chronic indications.
The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and atrial fibrillation, those with left ventricular assist devices, and potentially those with Kawasaki disease (KD), an acute, self-limited, febrile illness that primarily affects children under 5 years old and is the leading cause of acquired heart disease in developed countries. The Company recently submitted a request to the FDA for Rare Pediatric Disease Designation (RPDD) for tecarfarin for “Prevention of the Formation of Life-Threatening Blood Clots Inside Coronary Artery Aneurysms in Children with Kawasaki Disease”. Tecarfarin has also received Orphan Drug and Fast Track designations from the FDA.
For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.
Safe Harbor
Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include, without limitation, statements regarding the planned Phase 3 registration study of CAD-1005, the development of CAD-1005 to treat HIT; CAD-1005 potentially halting the core immune signaling pathway that drives platelet activation and vascular thrombosis; CAD-1005 being an essential add-on to standard anticoagulation; CAD-1005 unlocking a projected
For more information, please contact:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
